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Lung cancer is the leading cause for cancer death in both male and
female populations (American Cancer Society, Cancer Facts and
Figures – 1996). Lung cancer is a disease of heterogeneous
histologies and has been divided into 2 major groups: small cell
lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
NSCLC, accounting for 75% of lung cancers, falls into 3 major
types: squamous cell carcinoma (SCC), adenocarcinoma, large
cell carcinoma (LCC) and infrequently found carcinoids
(Srivastava and Kramer, 1994). 
Previous studies indicate that several molecular markers
involved in the initiation and progression of lung cancers are
useful in predicting prognosis in the early stage of the disease
(Kalemkerian, 1994; Stahel, 1995; Zhou et al, 1996; Carbone,
1997). Some marker antigen such as sialoglycoproteins have
been found specifically in SCLC while others such as high mole-
cular weight mucins have been found specifically in NSCLC.
Although many of these molecular markers have been shown to
be useful in early detection of lung cancer, their functions remain
unknown. 
Regulation of protein synthesis has increasingly been linked to
disruption of cell behaviour leading to cancer. It has been shown
that over-expression of factors of translation machinery such as
elongation factor EF1a (Tatsuka et al, 1992), initiation factors
eIF4E (Lazaris-Karatzas et al, 1990), eIF4G (Fukuchi-Shimogori
et al, 1997), eIF2a (Donze et al, 1995), and ribosomal protein S3a
(Kho et al, 1996), affect cell growth. Expression of eIF4E (De
Benedetti and Harris, 1999), the p48 of eIF3 (Asano et al, 1997b),
EF1g (Chi et al, 1992; Lew et al, 1992), and S3a (Pogue-Geile
et al, 1991) has also been found deregulated in tumours. 
In this paper, we report our finding that a 170-kDa protein was
over-expressed in human lung cancers and it was identified as the
putative p170 subunit of eIF3 by cDNA cloning. We also show
that p170 mRNA is ubiquitously expressed in all tissues tested
with high levels in adult proliferating tissues (e.g. bone marrow)
and tissues during development (e.g. fetal tissues). 
MATERIALS AND METHODS 
Cell lines 
HEK 293, HS-294T and Hep G2 were maintained in DMEM
containing 10% FBS. HL-60, GC-3 and, MDA-MB-231 cells
were maintained in RPMI-1640 medium containing 20% (for HL-
60) and 10% (for GC-3 and MDA-MB-231) FBS. IMR-90 was
grown in a-MEM containing 10% FBS, 1% L-glutamine, 1%
HEPES. SKOV3 cells were maintained in a-MEM supplemented
with 15% FBS. Vinblastine was added to the media to a final
concentration of 1 mg ml–1 for the maintenance of drug-resistant
SKOV/VLB cells. The CHO cell lines were maintained in a-
MEM medium containing 10% FBS. Colchicine was added to the
media to a final concentration of 30 mg ml–1 to maintain drug-
resistant CHrB30 cells. MCF-7 and its drug-resistant subclone
BC-19/3 cells were grown in Eagle’s IMEM supplemented with
10% FBS. To maintain the drug resistance of BC-19/3 cells 0.01
mM adriamycin was added to the medium. NIH-3T3 cells was
maintained in D-MEM containing 10% Donor Calf Serum and
1% L-glutamine. All cells (except NIH-3T3 that used 10% CO2)
were kept at 37˚C in a humidified atmosphere containing 5%
CO2. 
Generation of polyclonal antibody AbD 
The generation and purification of fusion protein antigen and anti-
body AbD were performed as previously described (Zhang et al,
1996). Briefly, a cDNA fragment encoding the loop linking puta-
tive TM7 and TM8 of hamster Pgp (see Figure 1 for the sequence)
was generated by PCR. The PCR product was treated with T4
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DNA polymerase and ligated into pGEX-2T vector linearized with
Sma I. The positive clone was used to generate fusion protein in
YT medium containing 2% glucose, and 100 mg ml–1 ampicillin
and induced by addition of 0.01 mM IPTG. Fusion protein was
purified with glutathione-conjugated Sepharose-4B from the
supernatant of the cell lysate and digested with 50 units of
thrombin for 5 h at room temperature. The Sepharose beads
containing GST and the supernatant containing the Pgp fragment
were separated by centrifugation at 500 g for 30 seconds. The
purified Pgp peptide (500 mg) in complete Freund’s adjuvant was
injected subcutaneously into a female New Zealand white rabbit.
150 mg of purified protein in incomplete Freund’s adjuvant was
injected as a first boost 30 days after the initial injection, and sera
was collected 2–4 times in one month 7 days after each boost.
Preimmune serum was collected as a control before the above
steps were taken. Affinity purification of the antisera was
performed using ImmunoPure immobilization kit from Pierce
following the supplier’s instructions. 
Isolation of human lymphocytes and macrophages 
Human lymphocytes and macrophages were isolated as previously
described (Harbeck et al, 1982). Briefly, 10 ml of whole blood
were loaded on top of a 45–72% Percoll step gradient and
centrifuged at 1500 g for 25 min at room temperature. After
centrifugation, macrophages at the interfaces between plasma and
45% percoll and lymphocytes at the interface between 45% and
54% percoll were collected, centrifuged and washed 2 times with
PBS. Final cell pellets were resuspended in hypotonic lysis buffer
(10 mM KCl, 1.5 mM MgCl2, 10 mM Tris/HCl, pH 7.4, 2 mM
PMSF) and membranes were isolated for Western blot analysis. 
Preparation of membrane fractions from human tissues 
Crude membranes were isolated from discarded human tissues
using methods as previously described (Riordan and Ling, 1979).
Briefly, 0.5 g of tissue was homogenized in 10 ml of hypotonic
lysis buffer using a tissumizer. The homogenate was then
centrifuged at 4000 g for 15 min to remove cell debris and nuclei.
The supernatants were centrifuged again at 100 000 g for 60 min
to enrich the membrane fraction. The final crude membrane pellet
was resuspended in 1 ml STBS (0.25 M sucrose, 10 mM Tris/HCl,
pH 7.4, 150 mM NaCl, 2 mM PMSF) and stored at –70˚C. 
Library screening 
About 300 000 plaques of a lgt11 cDNA library prepared from
HL-60 cell line (a generous gift from Dr Javier Navarro, UTMB,
Galveston, Texas) were screened using an affinity-purified AbD
probe (at 1:500 dilution) and a picoBlue Immunoscreening detec-
tion kit (Stratagene). One positive clone was found in the first
round of screening and the recombinant l DNA of the positive
clone was isolated. A cDNA insert of 2.4 kb was recovered by
PCR using vector primers (F: 5¢-GGTGGCGACGACTCCTG-
GAGCCCG-3¢ and R: 5¢-TTGACACCAGACCAACTGGTAAT-
G-3¢) and the PCR product was cloned into pGEM-T easy plasmid
and sequenced using an automated sequencer. To obtain the full-
length cDNA, 5¢-RACE PCR was performed using 2 antisense
p170-specific primers: GSP1: 5¢-TTCATCATCCCCCAGACG-3¢
and GSP2: 5¢-TTCTCTGTTCCTCGTAAGCGCTCT-3¢. A product
of 2.3 kb was generated, cloned and sequenced. 
Construction of the full-length cDNA of p170 
To construct the full-length sequence of p170, we used the cDNA
clones isolated by Johnson et al (1997). The full-length cDNA was
constructed as described by Valasek et al (1998). The resulting
plasmid carrying the full-length p170 was named pUC19-p170. To
engineer p170 into expression vectors, a 4.7-kb insert containing
full-length human p170 cDNA was excised from pUC19-p170 by
digestion with KpnI/BsaAI and cloned into pGEM-4Z plasmid. 
Peptide neutralization 
5 mg of crude membrane fractions from SKOV/VLB cells were
separated by SDS-PAGE for Western blot analyses. Different dilu-
tions (from 1:1000 to 1:100 000) of the AbD (0.45 mg ml–1) were
tested to determine the minimum dilution of AbD needed for a
consistently positive detection of p170. The minimal amount of
AbD needed for detection was neutralized by overnight pre-
incubation with excess amount of synthetic peptide. The antibody-
peptide complexes were microfuged at top speed for 15 min and
the supernatant was used to probe the Western blot. 
In vitro transcription and translation 
In vitro transcription and translation were performed as previously
described (Zhang and Ling, 1991). Briefly, full-length p170 in
pGEM-4Z plasmid was digested with Afl II, and the linearized
plasmid was used as template for in vitro transcription using SP6
RNA polymerase (Promega). In vitro transcripts were added to
rabbit reticulocyte lysate to program cell-free translation and the
translation products were analysed on SDS-PAGE by Western blot
or fluorography. 
Master blot analysis 
A probe corresponding to the coding region of p170 (bases
2253–3712) was obtained by digesting cDNA with Acl I and
Xho I. The probe was labelled using a random-primed labelling
kit (Boehinger-Mannheim). A master blot (Clontech) was pre-
hybridized for 30 min at 65˚C, in a quick hybridization solution
(Stratagene), followed by hybridization for 90 min at 65˚C in the
same solution containing 10 mg ml–1 salmon sperm DNA, 2 mg
ml–1 Cot-I DNA, 10 mg ml–1 tRNA, and ~1.25 ´ 106 cpm ml–1
probe. The blot were then washed twice in 2X SSC/0.1% SDS at
room temperature for 15 min each and once in 0.1X SSC/0.1%
SDS at 60˚C for 30 min. The blot was finally exposed to an X-ray
film at –70˚C for autoradiography. The signal density was deter-
mined using a Scion Image program. 
RESULTS 
Detection of p170 by polyclonal antibody AbD 
While studying multidrug resistance (MDR) in cancer cells, a
polyclonal antibody (AbD) against a peptide (FSKVVGVFTR-
NTDDETKRHDSNLFSLLFLILG) of Chinese hamster P-
glycoprotein (pgp1) was generated. The affinity-purified AbD
was tested for its specificity to Pgp in membrane fractions
isolated from hamster and human MDR cell lines using Western
blot analyses. In hamster, AbD specifically reacted with a 170-
kDa protein of drug-resistant CH
rB30, but not of sensitive Aux1522 R Pincheira et al
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B1 cells (Figure 1A, lanes 1 and 2). When the blot was probed
with the Pgp-specific monoclonal antibody (mAb) C219 (a gift
from Dr Victor Ling) (Georges et al, 1990), the same 170-kDa
protein was detected in CHrB30 cells (Figure 1B, lanes 1 and 2).
Thus, the 170-kDa protein in CHrB30 cells detected by AbD is
Pgp. In contrast, in human drug-sensitive (MCF-7 and SKOV3)
and resistant (BC19 and SKOV/VLB) cancer cell lines AbD
reacted with a 170-kDa protein (p170) that was not recognized
by mAb C219 (compare lanes 3–6 in Figure 1A and 1B). Note
that p170 in drug-resistant SKOV/VLB cells (Figure 1A, lane 6)
has a slower mobility than Pgp on SDS-PAGE (Figure 1B, lane
6) (170 kDa versus 160 kDa) and that mAb C219 is known to
react with both human and hamster Pgp. The different amino
acids between human and hamster Pgp may comprise the AbD
epitope which exists in human p170 (Figure 1C). To confirm
p170 is not Pgp, we examined the post-translational modification
of p170. As shown in Figure 1D, endoglycosidase treatment
reduced the size of Pgp detected by C219 (compare lanes 1 and
2). However, the size of p170 detected by AbD was not changed
(Figure 1D, lanes 3–4). Thus, p170 is not a glycoprotein and it is
different from Pgp. 
Expression of p170 in human cancer cell lines 
Because p170 is expressed similarly in both drug-resistant and 
-sensitive human cancer cells, it is not likely to be related to drug
resistance. Thus, we questioned whether p170 expression is related
to cell proliferation and/or malignant transformation. To answer
this question, we tested 6 more human cancer cell lines (A2780,
MDA-MB-231, HS-294T, HepG2, HL-60, GC-3), one normal
human lung fibroblast cell line (IMR-90), and normal lymphocytes
and macrophages. As shown in Figure 2, p170 expression is
elevated in all cancer cell lines as compared to the normal cells
using a housekeeping protein calnexin as an internal control. Thus,
it is possible that increased p170 expression is related to cell
proliferation and/or malignant transformation. 
Expression of p170 in human cancer tissues 
To determine whether p170 over-expression is relevant to tumori-
genesis, we tested p170 expression in cancer and normal human
tissues (obtained from Cooperative Human Tissue Network).
Crude membrane fractions from human ovary, kidney, lung,
breast, and colon were isolated and analysed by Western blot
(Figure 3). We found a significant difference of p170 expression
only between lung cancer and its corresponding normal tissue.
Lung cancer tissues express a high p170 level whereas normal lung
tissues express low and undetectable levels of p170 (Figure 3A,
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Figure 1 The difference between p170 and Pgp in human cells. A & B
detection of p170 and Pgp. 5 mg membranes of Aux B1, CHrB30, MCF-7,
BC19, SKOV3, and SKOV/VLB was probed on a Western blot with affinity-
purified polyclonal antibody AbD (panel A) or Pgp-specific monoclonal
antibody C219 (panel B). C, comparison between the sequence of Chinese
hamster Pgp (top, GenBank accession number M60040) used to generate
AbD and that of human Pgp (bottom, GenBank accession number M14758).
The boxed sequence indicates the potential epitope for AbD. The dashed line
represents the same amino acids between the 2 sequences. D, glycosylation
status of p170. 5 mg of crude membranes from BC19 cells were digested with
(lanes 2 and 4) or without (lanes 1 and 3) endoglycosidase PNGase F
followed by Western blot probed with C219 (lanes 1–2) or AbD (lanes 3–4)
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Figure 2 Expression of p170 in cancer and normal cell lines. Crude
membranes were prepared from cell lines of human ovarian cancer A2780
(lane 1), breast cancer MDA-MB-231 (lane 2), melanoma HS-294T (lane 3),
hepatoma HepG2 (lane 4), leukaemia HL-60 (lane 5), colon cancer GC-3
(lane 6), normal lung fibroblast IMR-90 (lane 7), normal lymphocytes (lane 8),
and normal macrophages (lane 9). 5 mg crude membranes were used for
Western blot analysis probed with AbD. Calnexin was used as a control for
protein loading. Panel B shows p170 expression level normalized to calnexin
of panel A as determined using Scion image software 
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Figure 3 Expression of p170 in human tissues. A, detection of p170 in
human tissues. 5 mg crude membranes from normal or cancer human liver
(Li), lung (Lu), colon (C), breast (B), kidney (K), and ovary (O) were
subjected to Western blot analysis probed with AbD. B, Coomassie blue
staining of protein profile of membranes of human tissues as shown in (A).
About 30 mg of proteins each was resolved on a SDS-PAGE and stained with
coomassie blue Lung cancer and eIF3 P170 1523
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lanes 2 and 8). P170 expression level was undetectable in other
cancer tissues compared to their corresponding normal tissues
(Figure 3A, compare lanes 1, 3–6 with lanes 7, 9–12, respec-
tively). It is, however, interesting to note that high expression level
of p170 was found in both normal and cancer ovarian tissues. 
Table 1 summarizes the results of all human tissues analysed. Of
the 18 lung-cancer samples examined, 15 had elevated expression
of p170 and only one of the 10 normal corresponding tissues had a
detectable level of p170. Only one each of 5 cases of breast, colon
and liver tumours has elevated expression of p170. Table 2 shows
the correlation between the elevated expression of p170 and
the types of lung cancers. Apparently, all types of lung cancers
express elevated level of p170. We also analysed clinical
parameters such as age, histology and treatment history of the lung
cancer patients tested. Table 3 summarizes the nature of human
lung tissues used and no apparent correlation was found between
p170 expression and the clinical parameters considered. 
Cloning of p170 
To identify p170, we cloned p170 cDNA from a lgt-11 cDNA
expression library. The full-length cDNA of 4.5 kb encodes a
protein of 1382 amino acids (Figure 4A). By searching the
GeneBank, we found that the p170 cDNA encodes the 170-kDa
subunit of eIF3 (Johnson et al, 1997). Analysis of the deduced
amino acid sequence showed that there was a stretch of 5 amino
acids RNTDD (underlined in Figure 4) which is the same as in
hamster but not in human Pgp (see the boxed sequence in Figure
1C). Thus, it is possible that RNTDD represents the AbD epitope
responsible for AbD detection. 
The eIF3 p170 cDNA was confirmed by 4 experiments. Firsly, a
synthetic peptide (TRNTDDE) was able to inhibit the reactivity of
AbD to p170 but not the irrelevant antibody C219 (compare
Figure 5A with Figure 5B). Thus, RNTDD may represent AbD
epitope and likely AbD reacts with eIF3 p170 (Johnson et al,
1997). Secondly, antibody AbF against the fusion protein gener-
ated from eIF3 p170 cDNA (Johnson et al, 1997) detected the
same p170 on Western blot detected by AbD (Figure 5C, lanes 1
and 3) as well as with the p170 immunoprecipitated by AbD
(Figure 5C, lanes 2 and 4). Thirdly, eIF3 p170 cDNA (Johnson
et al, 1997) was translated in rabbit reticulocyte lysate (RRL) and
the translation product of 170-kDa reacted strongly with AbD on
Western blot (Figure 5D, lanes 1 with 2–5) and by immunoprecip-
itation (data not shown). Lastly, the higher level of p170 was
detected in human lung cancer cell line H1299 than in normal lung
fibroblast IMR90 by eIF3 authentic antibodies AbF (Johnson et al,
1997), M116 (Johnson et al, 1997), and eIF3 antiserum (Meyer
et al, 1982). 
Amino acid sequence analysis of p170 
To examine what important functional domain p170 may have, we
searched p170 amino acid sequence against several protein motif
databases. Two main interesting motifs were identified with p170
sequence, which have not been reported previously. One is a PCI
domain from amino acid 405 to 495 (double-boxed amino acid
sequences, Figure 4A and 4B) and the other is spectrin repeats
(single-boxed sequences, Figure 4A and 4B). The PCI domain
(Hofmann and Bucher, 1998) consists of pure a-helical structures
of ~200 amino acid residues generally located at the C-terminus of
the protein. It has been found in yeast and mammalian Proteasome
regulatory components, in plant COP9-complex proteins involved
in light signalling and in translation Initiation factor 3 complex
subunit p110 and p48 (Hofmann and Bucher, 1998). Because
proteins containing this domain are all part of a large multi-protein
complex, it is possible that the PCI domain plays a role in
protein–protein interaction. The PCI domain in p170 may play an
important role in its interaction with eIF4B, p44 and p116 of eIF3.
The spectrin repeat is a major constituent of several proteins
belonging to the spectrin family of actin-binding proteins. Spectrin
is a major component of the membrane cytoskeleton and the spec-
trin repeat is made up of 3 a-helices separated by 2 loop regions
(Pascual et al, 1997). Another interesting domain in the p170
amino acid sequence is a 10 amino acid tandem repeat (in grey,
Figure 4). This repeat has been reported previously (Nagase et al,
Table 2 Correlation between P170 expression and lung cancer histology 
Histology No. of P170(+)/Total 
SCLC 2/2 
LCC 2/3 
SCC 7/7 
AC 4/6 
Table 1 Detection of P170 protein in normal and cancer human tissues 
Cancer Normal 
Tissues No. of P170(+)/Totala No. of P170(+)/Totala
Kidney 0/4 0/4 
Ovary 4/4 4/4 
Breast 1/5 0/4 
Colon 1/5 0/4 
Liver 1/5 0/2 
Lung 15/18 1/10 
aNumber of cases that show a positive signal of p170 detected by AbD on
Western blot over total number of tissues tested. 
Table 3 Nature of lung cancer tissues tested 
Sample Age/Sex Treatment Differentiation stagea P170b
SCLC 60/M Yes P + 
SCLC N/A N/A P + 
LCC 60/F No U – 
LCC 70/M Yes P + 
LCC 66/F No P + 
SCC 70/M No M/P + 
SCC 65/F Yes M/P + 
SCC 73/F N/A M + 
SCC 75/M No P + 
SCC 67/F No M + 
SCC 60/M No P + 
SCC 47/M N/A P + 
AC 73/M N/A P + 
AC 68/M No P + 
AC 81/F N/A M – 
AC 68/M N/A D + 
AC 43/M No M – 
AC 62/F Yes M + 
aThe differentiation stage of the cancer tissues are categorized as U
(undifferentiated), P (poorly differentiated), M (moderately differentiated), 
and D (differentiated). bP170 expression was detected (+) or not detected (–)
using AbD on Western blot. 1524 R Pincheira et al
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1995; Bachmann et al, 1997; Johnson et al, 1997; Scholler and
Kanner, 1997) and was suggested to have a role in the interaction
between p170 and eIF4B (Methot et al, 1996). 
Expression of p170 mRNA in human tissues 
In the above studies, we showed that the expression of p170
protein was elevated in cancer cell lines and in lung cancer tissues
on Western blot. To further understand the expression of p170, we
probed an array of RNAs from various normal adult and fetal
human tissues with p170 cDNA. As shown in Figure 6B, all
tissues expressed p170 mRNA but at different levels. It is inter-
esting to note that the proliferating tissues such as bone marrow
(E8), thymus (E5), and digestive tissues (C8, D3) express highest
mRNA levels. Also, most fetal tissues express higher level of p170
mRNA than the corresponding adult tissues. For example, the
expression level in fetal lung (G7) is ~3 times more than that in
adult lung (F2). This observation suggests that higher expression
level of p170 is required for cell proliferation and tissue develop-
ment. 
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Figure 4 Sequence of p170. Amino acid sequence is shown in single letter codes and the untranslated regions are shown in small letters. The double- and
single-boxed amino acid sequences are the putative PCI domain and the putative spectrin repeat, respectively. The shaded region is the domain of 10 amino
acid repeat. AbD epitope RNTDD is shown underlined. The arrowhead in B indicates the relative position of AbD epitope Lung cancer and eIF3 P170 1525
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DISCUSSION 
In this paper, we report our findings that p170 is over-expressed in
human lung cancers and in cultured cancer cell lines compared
with normal lung tissues and normal cells, respectively. The p170
protein was identified to be eIF3 p170 by cDNA cloning, charac-
terization, and detection of p170 in human lung cancer cell line
using antibodies directed against eIF3 p170 (AbF, M116, and
eIF3). The cDNA was confirmed to encode the 170-kDa protein
detected in cancer cells by (a) in vitro translation, (b) immunopre-
cipitation and Western blot with antibody AbF, (c) AbD epitope
identification, and (d) detection of p170 over-expressed in human
lung cancer cells with authentic eIF3 p170 antibodies. Thus, we
conclude that eIF3 p170 is the p170 over-expressed in human lung
cancers. 
eIF3, a translation initiation factor, consists of 8 or more protein
subunits (Asano et al, 1997a). It plays a key role in protein
synthesis by interacting and stabilizing the ternary complex of
eIF2.GTP.Met-tRNAi and by helping the binding and stabilization
of the Met-tRNAi on 40S ribosomal subunits (Trachsel et al, 1977;
Benne et al; 1979; Asano et al, 1997a). One of the eIF3 subunits,
p170 (Johnson et al, 1997), has been demonstrated to interact with
other components of the eIF3 such as p44 (Block et al, 1998) and
p116 (Methot et al, 1997), and also with eIF4B (Methot et al,
1996) as well as RNA (Block et al, 1998; Buratti et al, 1998).
Because of its interaction with RNA and multiple proteins, p170
has been postulated to play an important role in all eIF3 functions
(Johnson et al, 1997; Block et al, 1998; Valasek et al, 1998). P170
has also been suggested to play a role in the cap-independent
translation (Buratti et al, 1998). However, it has been observed
that eIF3 preparations, which essentially lacked p170, did not
differ substantially in specific activity from preparations relatively
rich in p170 (Meyer et al, 1981). This is supported by a recent
study (Chaudhuri et al, 1997) which showed that purified eIF3
complex lacking p170 was able to stimulate the binding of the
ternary complex to 40S ribosome. This observation indicates that
p170 may not be a true subunit of eIF3, but only interact with the
eIF3 complex in a discrete step in the translation initiation process.
P170 could also, under specific conditions, dissociate from eIF3
complex and exert other specific function(s) (Chaudhuri et al,
1997; Valasek et al, 1998). 
Previously, a p170 homologous protein (p150) cloned from
mouse has been found over-expressed in human breast, cervical
and esophageal cancers (Bachmann et al, 1997; Dellas et al, 1998;
Chen and Burger, 1999). We also analysed p170 expression 
in human breast tissues. However, p170 over-expression was
found in only one of the 5 samples examined (Table 1). The cause
for the difference between this study and that of Bachmann et al
(1997) is not known. However, it is possible that different
isoforms of p170 is over-expressed in different cancer tissues.
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Figure 5 Confirmation of eIF3 p170 cDNA clone. A and B, peptide inhibition
of AbD and C219 reaction. AbD (A) and C219 (B) were preincubated without
(lane 1) or with epitope peptide (lanes 2 and 3) prior probing a Western blot
of SKOV/VLB membranes. C, immunoprecipitation of p170. Cell lysates of
SKOV/VLB were precipitated by AbD and analysed by Western blot using
AbF (lanes 1–2) or AbD (lanes 3–4). Lanes 1 and 3 are control SKOV/VLB
membranes. D, in vitro translation of p170 cRNA. P170 cRNA was
transcribed from p170 cDNA and used to programme cell-free translation in
rabbit reticulocyte lysate in the presence of [35S]methionine (lanes 2–5).
Translation products were then separated by SDS-PAGE for autoradiography
(AR) and Western blot (IB) analysis. Lane 1 is the control membrane from
SKOV/VLB cells. Note that endogenous p170 in rabbit reticulocyte lysate 
was not detected by AbD possibly due to lack of AbD epitope in rabbit p170.
E, Western blot analysis of H1299 and IMR90 cells with eIF3 antibodies. 
10-mg proteins from lung cancer cell line H1299 and normal lung fibroblast
IMR90 were subjected to Western blot analysis. Antibodies used are AbD,
AbF (Johnson et al, 1997), M116 (Johnson et al, 1997), and eIF3 antiserum
(Meyer et al, 1982) 
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Figure 6 Master blot of human tissues. A master blot containing total RNAs
isolated from various adult and fetal human tissues was probed with p170
(panel B) and ubiquitine (panel C) probes. Panel A indexes the tissues used.
Panel D represents the relative intensity of p170 in panel B determined using
Scion Image and normalized against the corresponding intensity of ubiquitine
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Nevertheless, both Bachmann’s and our studies suggest that
p150/p170 over-expression correlates with cancers in human
breast, cervix, esophagus and lung. 
In this study, we found no correlation between p170 over-
expression and clinical parameters such as age, histology, and
treatment history of the lung cancer patients tested. However, a
correlation has been found between cancer progression and p150
(mouse homologue of human p170) expression in cervical
cancers. The highest p150 level was found at the begining of the
malignancy and the level decreased with cancer progression
(Dellas et al, 1998). P150 expression has also been found to corre-
late with the cell differentiation (Bachmann et al, 1997). The more
differentiated cells express less p150 or vice versa. 
It is unknown why p170 is not detected in the membrane frac-
tion of normal human lung tissues considering that it may be a
subunit of eIF3 and its mRNA is expressed in normal tissues.
However, it has been shown that p170 could not be detected in
many normal human breast tissues (Bachmann et al, 1997).
Furthermore, although eIF3 is a ubiquitous and necessary factor
for protein synthesis, it has also been shown that p170 may not be
necessary for the function of eIF3 (Chaudhuri et al, 1997). P170
may be a protein co-isolated with eIF3 and it may not be constitu-
tively expressed at the protein level. Considering the high GC
content (70%) and a potential secondary structure in the 5¢-UTR of
p170, its expression may be under translational control. 
Although it is currently unknown whether over-expression of
p170 in human lung cancer is a result or potentially a cause of lung
tumorigenesis, it is interesting to note that the p170 mRNA is highly
expressed in the rapid proliferating tissues such as bone marrow and
thymus and in the developing fetal tissues. Together with the study
of mouse homologue p150 (Bachmann et al, 1997), this observation
suggests that p170 over-expression may be important for cell
growth, proliferation and tumorigenesis. The possibility that a
subunit of eIF3 may be involved in lung tumorigenesis is also in
agreement with the important role of protein synthesis in cell-
growth, differentiation and transformation. eIF3 is a key element in
the protein translation initiation step. Through its binding to the 40S
ribosomal subunits, eIF3 plays important roles in several different
steps of the translation initiation process, including dissociation of
ribosome (Trachsel et al, 1977), binding and stabilization of the
ternary complex (Trachsel et al, 1977; Benne et al, 1979), and
binding of mRNA (Goumans et al, 1980; Naranda et al, 1994;
Lamphear et al, 1995; Buratti et al, 1998). It is possible that disrup-
tion of the normal function of eIF3 complex by over-expressing one
of its subunits such as p170 can lead to abnormal cell growth.
Recently, the p40 subunit of eIF3 was also found over-expressed in
human breast and prostate cancers (Nupponen et al, 1999). 
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